PBM lowers co-pay for CFC-free inhalers
UnitedHealth Pharmaceutical Solutions (UHPS) lowered the co-pay for CFC-free brand-name inhalers.
UnitedHealth Pharmaceutical Solutions (UHPS) lowered the co-pay for CFC-free brand-name inhalers. UHPS has moved Xopenex HFA to Tier 1-the lowest co-pay tier-on its prescription drug list so that commercial members have an affordable, effective way to continue managing their asthma without supply issues or added cost. As a result, the co-pay for CFC-free Xopenex ranges from $5 to $10, depending on the member’s co-pay benefit. CFC-containing albuterol inhalers, the industry standard for 25 years, are being phased out because of their harmful effect on the earth’s ozone layer. The new CFC-free brand-name inhalers, according to UHPS, are just as effective but have a higher cost.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
